DataMEDS completes first compounded peptide sale
Key points
- DataMEDS AI announced that its Corexa Pharmacy subsidiary completed its first commercial sale of a compounded peptide under the HHS Enforcement Discretion Policy.
- The sale involved one of six peptides identified by the FDA's Pharmacy Compounding Advisory Committee, but the compounded drugs are not FDA-approved and have not been evaluated for safety or efficacy.
- DataMEDS is developing its pricing model and plans to market the offering to prescribing physicians through its pharmacy and distribution network.
DataMEDS AI (NASDAQ:MEDS) announced that its Corexa Pharmacy subsidiary completed its first commercial sale of a compounded peptide under the U.S. Department of Health and Human Services' Enforcement Discretion Policy.
The sale involved one of six peptides identified by the FDA's Pharmacy Compounding Advisory Committee at its July 23–24, 2026 meeting: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax.
The company is finalising its pricing model and plans to market the offering to prescribing physicians, with compounded medications prepared for individual patients under applicable prescription requirements.
DataMEDS operates Corexa Health, which provides pharmacy dispensing and distribution services, alongside its health technology platforms, including EinsteinRx and PharmacyChain.
The HHS policy provides interim enforcement discretion for specified peptide compounding under Section 503A, subject to conditions including ingredient testing, patient-specific prescriptions and safety reporting, but does not make the compounded drugs FDA-approved.
